• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of April 22

News
Video

Here are the top 5 biosimilar articles for the week of April 22, 2024.

Number 5: Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.

Number 4: Tyenne (tocilizumab-aazg) was the second tocilizumab biosimilar to be FDA approved, but it is the first to launch in the US.

Number 3: Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.

Number 2: Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.

Number 1: High rates of biosimilar uptake in the American Oncology Network (AON) have saved the organization over $243 million between 2020 and 2023, according to Melody Chang, vice president of pharmacy operations at AON.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Here are the top 5 biosimilar articles for the week of May 13, 2024.
Jeffrey Casberg, RPh, MS.
The Top 5 Center for Biosimilars Articles for the Week of May 6, 2024.
Here are the top 5 biosimilar articles for the week of April 29, 2024.
Related Content
© 2024 MJH Life Sciences

All rights reserved.